For monitoring patients treated for prostate cancer, Prostate Specific Antigen (PSA) is measured periodically after they receive treatment. Increases in PSA are suggestive of recurrence of the cancer and are used in making decisions about possible new treatments. The data from studies of such patients typically consist of longitudinal PSA measurements, censored event times and baseline covariates. Methods for the combined analysis of both longitudinal and survival data have been developed in recent years, with the main emphasis being on modeling and estimation. We analyze data from a prostate cancer study that has been extended by adding a mixture structure to the survival model component of the model. Here we focus on utilizing the model to make individualized prediction of disease progression for censored and alive patients.
In this model each patient is assumed to be either cured by the treatment or susceptible to clinical recurrence. The cured fraction is modeled as a logistic function of baseline covariates, measured before the end of the radiation therapy period. The longitudinal PSA data is modeled as a non-linear hierarchical mixed model, with different models for the cured and susceptible groups. To accommodate the heavy tail manifested by the data and possible outliers, we use a t-distribution for the measurement error. The clinical recurrences are modeled using a time-dependent proportional hazards model for those in the susceptible group where the time dependent covariates include both the current value and the slope of post-treatment PSA profile. Estimates of the parameters in the model are obtained by the Markov chain Monte Carlo (MCMC) technique. Residuals from the longitudinal model are plotted for model checking. The model is used to give individual predictors for both future PSA values and the predicted probability of recurrence up to four years in the future. These predictors are compared with observed data from a validation data set consisting of further follow-up of the subjects in the study. There is good correspondence between the predictions and the validation data.
are frequently important health indicators that represent the progression of a disease. Such data will typically have additional features and complications associated with it, including the presence of treatment group indicators and baseline covariates, measurement error in the biomarkers and right censoring of the event time with the possibility of dependent censoring. Joint models for both the marker process and the survival data have been developed in recent years to analyze such data. Estimation of the parameters can be done through a two-stage approach (e.g. Tsiatis et al. 1995, Bycott and Taylor 1998 ) and a likelihood based approach (e.g. Faucett and Thomas 1996 , Wulfsohn and Tsiatis 1997 , Henderson et al. 2000 , Wang and Taylor 2001 , Xu and Zeger 2001 , Pauler and Finkelstein 2002 , Law et al. 2002 . A review on these two approaches can be found in Yu et al. (2004) .
PSA is a well known biomarker for prostate cancer used both for screening and for monitoring response to treatment. It is a routine laboratory assay obtained in a blood sample and thus is easy to acquire. Common treatments for patients with local prostate cancer include radiation therapy and surgery. After treatment, clinical recurrence of disease may occur after a period of time. Clinicians and patients monitor the outcome of the treatment by measuring PSA regularly and slight changes or increased values can be a source of great concern and anxiety. In patients who undergo radiation therapy, a sharp rise in PSA after the initial decline is an indicator of treatment failure, and clinical recurrence (reappearance of tumor, either local recurrence or distant metastasis) is expected to follow, although it could be many years before there is clinical manifestation of the recurrence. If the PSA remains low and stable this is an indication that the tumor is not regrowing in the patient. Thus the longitudinal PSA could be useful for predicting cancer recurrence for patients after radiation therapy. The latest value of PSA and the slope of its increase can be very informative about the progression of disease and the hazard of a clinical recurrence. If the pattern of PSA is suggestive of an increased risk of clinical recurrence, the patients may be put on new therapy based solely on this pattern of PSA, typically hormonal therapy with substantial potential side effects, to slow down progression of the disease. Thus methods that enhance early detection of recurrence and accurate prediction of future disease progression for an individual patient based on the pattern of PSA values can have great utility.
A feature in many cancer applications is the fact that some of the patients may have their tumor completely killed by the treatment, and so will never experience clinical recurrence. These patients are considered to be "cured". We incorporate this aspect of the study into our joint modeling by using mixture cure models (e.g. Farewell 1982 , Kuk and Chen 1992 , Taylor 1995 .
The longitudinal-survival-cure model we adopt here has been used in Law et al. (2002) and Yu et al. (2004) . The previously developed model is extended in a number of ways. Besides including additional baseline covariates, we use a time-dependent proportional hazards model depending on hormonal therapy (HT), the current slope, as well as the current value of PSA. To accommodate heavy tails manifested in the longitudinal data and possible outlier, t distributions are used for the measurement error. This model allows estimation of a number of different aspects, including both how PSA changes over time and how this is influenced by other covariates and how PSA influences the hazard of clinical recurrence. However the main focus of the article is on utilizing the model to make individualized predictions for disease progression. Specifically, we predict future PSA values and cancer recurrence probabilities for censored and alive patients. The performance of the prediction is evaluated using a validation data set obtained through further follow-up for these patients.
The task of using a series of biomarker values is considerably more complicated than using a single value, for early detection of disease or monitoring disease progression. The hope is that by using all the data from the serial observations this will lead to an earlier and more precise prediction of future disease progression. There are a few examples of using serial observations in the statistical literature, all involving fairly complicated models and considerable computation.
These include using CA125 for early detection of ovarian cancer (Skates et al. 2001) , using PSA for early detection of prostate cancer (Slate and Cronin 1997) , and using PSA for detecting disease recurrence in prostate cancer (Pauler and Finkelstein 2002) .
The rest of this article is organized as follows. In Section 2, we describe two data sets, an analysis data set and a validation data set. In Section 3, we describe a joint cure model. Section 4 presents the Bayesian estimation schemes for the model. Section 5 lists the results. Section 6 uses the model to make individualized predictions and Section 7 assesses the performance of the prediction by comparison to a validation dataset. Finally, we conclude the article with a discussion section.
The joint model is developed and fit to one dataset, called the analysis dataset. Predictions derived from this dataset are compared with observations in a second dataset, called the validation dataset, which consists of further follow-up on the subjects in the analysis dataset.
Analysis dataset.
The data consist of 928 patients with localized prostate cancer, who were treated with external beam radiation therapy at the University of Michigan between July 1987 and February 2000.
Patients were excluded from this analysis if they received planned hormonal therapy before the end of the radiation therapy regimen. The baseline variables were age, radiation dose, and duration, T-stage(a measure of the size and location of the tumor), Gleason score ( a measure of the aggressiveness of the tumor) and pre-treatment PSA. Earlier version of these data are described elsewhere (Sandler et al. 2000) . increase. The PSA profiles are different among the three groups. We see a clear trend of PSA increase at the later follow-up time after the initial decline for failed patients while we see much flatter curves for censored patients. For patients who received HT as a salvage therapy, we also see a rising trend of the PSA measurements. This is expected because HT is usually given because of a rising pattern of PSA.
Validation dataset.
The validation dataset consists of all data collected on these 928 patients after 
Notation and Model Specification
Let z i = {z i1 , · · · , z iq } be the q fixed baseline covariates for subject i. The n i post-treatment PSA measurements of an individual are denoted by vectorỹ i = (ỹ i1 , · · · ,ỹ in i ), with the corresponding measurement time vectort i = (t i1 , · · · , t in i ). We denote log transformed post-treatment PSA measurements by
). This transformation is used so that residuals better satisfy the assumptions of symmetry and homogeneity of variance.
Let t i be the observed follow-up time, and δ i be the corresponding censoring indicator. The cure group indicator is denoted by D i . For a subject i in the susceptible group, D i is equal to 1; otherwise, it is equal to 2. Let x i,obs = {y i , t i , δ i } be the observed response data for subject i and X obs = {x i,
Incidence model
The probability of an individual i to be in the susceptible group is given by the logistic function:
(1)
Longitudinal model
The post-treatment PSA data are modeled by a hierarchical nonlinear mixed effects model.
The response model of PSA is given by
where P SA * ij ≡ P SA * (t ij ) is the "true" PSA process at time t ij the expression of which is defined below, ǫ ij is the measurement error at time t ij . We assume that the measurement error terms ǫ ij follow a mean 0 t-distribution with degree of freedom ν > 0, and variance σ 2 e for all
We note that the t-distribution can be written as a scale mixture of normal distributions (Lange et al. 1989) , that is, we can introduce a latent variable ζ ij such that
The "true" PSA marker process is modeled by a nonlinear exponential decay and exponential growth model (Zagars and Pollack 1993) :
r i1 , r i2 , r i3 and r i4 are the unobserved random effects for subject i (r i1 , r i2 , r i3 and r i4 > 0). The term (r i1 + r i3 ) is the intercept of the post-treatment PSA profile, r i2 is the rate of decline of PSA following treatment, while r i4 is the rate of rise following the initial decline.
Depending on the patient's cure status D i , we use different mixed effect model parameters for the true underlying marker profile. For the random effects of a subject i in the susceptible group, we assume
where R i denotes the log random effects (log r i1 , log r i2 , log r i3 , log r i4 ) and Z
( 1) i µ 1 is the mean vectors of the random effects in the susceptible group, Z
between I 4 and z * i , a vector of baseline covariates.
For the random effects of a subject i in the cured group, we assume that the rate of rise denoted by r i4 is close to zero:
where
i µ 2 is the mean vector of these random effects in the cure group where Z (2) i = (I 3 ⊗ z * i ) T . The mean −6 for R i4 for a cured patient is chosen from the fact that PSA level doubles on average in about 20 years for a healthy male.
Hence the covariance matrix Σ * 2 of R i for the cured group is block-diagonal with two blocks, Σ 2 and σ 44 . We assume a normal model for R i4 to allow for variations of the growth in the cured group.
Conditional failure time model
Conditional on the unobserved random effects, the relative hazard function of the event time t is given by
where the baseline hazard function is taken to be Weibull λ 0 (t|η) = αλt α−1 , g(·) is some continuous function, sl i (t) = ∂P SA i (t)/∂t is the slope of P SA i (t) ≡ log(P SA * i (t) + 1) at time t, and HT i (t) is a function of t representing HT effect. Our choice of including the slope of the underlying PSA curve is based on commonly used empirical criteria in characterizing prostate cancer progression such as PSA doubling time and PSA velocity. Due to the fact that only a small number of patients receiving HT and an even smaller number of these patients had events,
we take a simple function form for HT, HT i (t) = 1 − t−th i a I(th i < t < th i + a) where th i is the time of the HT if the patient has HT, a is a constant to be determined, and I(·) is the indicator function. Hence HT i (t) = 1 when t = th i and it decreases linearly to 0 at t = th i + a. The reason for taking a decreasing function for HT is that the effect of HT tends to diminish as time progresses.
We explore the appropriate functional form g for sl i (t), a in HT i (t), and the degree of freedom ν in the t-distribution through exploratory analysis. As an initial step, we fit a joint-longitudinalsurvival cure model to the analysis data set without taking any transformation of slope, that is, data. Then we use results of this modeling fitting to determine g, a, and ν. To choose a value for a, we regard all patients with clinical events or HT, and patients with estimated probability of D = 1 greater than 0.6 as "susceptible" and then we fit a Cox model to this group. Then we vary a from 0 to 120 and then compare the partial log-likelihood of each model fitting, and find that 60 may be a good choice for a. To determine a transformation g(·), we use the Poisson and spline-based method described in Therneau and Grambsch (2000) (pg. 120) to explore the functional form for g(·). We find that a square root transformation maybe appropriate. The residuals from the fitting of the longitudinal model is used to determine ν. The degree of freedom 5 is suggested for ν from plots of residuals quantiles versus quantiles of standard normal and t-distributions with various degrees of freedom.
Estimation Using Markov Chain Monte Carlo

Prior Distributions
We fit the model using a MCMC technique. Data driven vague normal priors are taken for b, γ, ω, κ, β. Specifically, we treat all censored patients with censoring time > 60 months and last longitudinal PSA < 4 as cured. Then we fit a logistic model to all patients in order to get the mean of the normal prior for b, we set the prior variance of each component of b as 16, which is approximately 100 times the variance estimate from this simple method. Similarly, we obtain prior means of γ, ω, κ, β by fitting a Cox proportional hazard model to non-cured patients from the above simplified rule and using the nearest preceding value of PSA as the current value. The An inverse Gamma distribution with mean 0.1 and variance 2 is used as the prior for σ 44 . The reason we use 0.1 for the mean is that there should be less variation for r i4 for the cured group.
From the posterior distribution of σ 44 , we can see that the posterior is dominantly determined by data. For the parameter λ of the baseline hazard, the prior is taken from a gamma distribution with mean 0.01 and variance 100. For the shape parameter α of λ 0 (t), we assume that it has uniform prior on [0.5, 2.5].
Posterior Distributions and Implementation Details
The posterior distributions for all the parameters can be obtained from the product of full complete data likelihood and prior distributions. The full complete data likelihood is determined by model components (1), (2), (3), (4), (5), and (6) specified in section 3 given the fully observed data
where N y ij | D i = 1, R i , σ 2 e /ζ ij and N y ij | D i = 2, R i , σ 2 e /ζ ij are the normal density for transformed longitudinal data from (2) conditioning on their incidence group,
the density function of the conditional failure time model for subjects in the susceptible group. iterations of burn-in.
Results
The main parameter estimates from the model fitting are listed in Table 1 . We show the posterior mean and standard deviation derived from the posterior draws of the parameters in the table. We compare the ratio of posterior mean over posterior standard deviation of a parameter and then compare with 1.96 to assess the significance of covariate effects. Table 1 shows the result for the incidence model (1), we find that a patient's tumor stage, baseline PSA and total dose of radiation are significantly related to the probability of cure in the expected direction. Gleason score, age, and Duration of the treatment are not significant.
For the conditional failure time model, we see that the slope of PSA profile affects the hazard of cancer recurrence greatly. Large slope highly increases the hazard. HT reduces the risk while higher Gleason score and baseline PSA are associated with elevated risk for not cured patients.
We use residuals from the fitting of the longitudinal model, y ij − P SA ij , to check the model where
with
i3 , and R
i4 are from the MCMC output for k = 1, · · · , K. We plotted the absolute residuals |y ij − P SA ij | versus predicted log-transformed current PSA from (8), baseline PSA, Gleason score and Tumor stages, we see no clear trend in any of these plots. Figure 2 shows a normal and a t 5 quantile-quantile plots of the residual. We see that the t distribution with 5 degrees of freedom is reasonable. We note that using a t distribution has the ability to accomodate outliers but had little impact on the results of parameter estimates listed in Table 1 . 
Model Predictions
Suppose we wish to forecast the t 0 months recurrence free probability P T i > t i +t 0 | X obs , Z for a censored patient i (still alive at the censored time t i ) based on the available data X obs , Z. Let Ω ≡ {b, σ e , µ 1 , µ 2 , Σ 1 , Σ 2 , γ, ω, κ, α, λ} denote the population parameters in the joint models described in Section 3.
is calculated from (6).
We consider two conditional survival curves 4 years after the last contact time for patient i, P T i > t i + t | X obs , Z, no HT in [t i , t i + t] and P T i > t i + t | X obs , Z, HT at time t i for Without HT given during the 4 years after the last contact time t ∈ (0, 48]. By putting these two prediction curves together, we can see the effect of HT on the patient's survival and help aid the decision of whether to give HT for him. Uncertainty of the prediction probability, say,
i } and calculating the variability of the predicted probability. Figure 3 shows the pattern of PSA and the predicted probability of future clinical recurrence from the date of last contact, with and without the addition of hormonal therapy at the last contact time, for four selected patients. Figure 4 shows the uncertainty of the prediction of clinical recurrence without HT, for the same set of four patients. The estimated probability of eventual recurrence for each patient is also listed in this figure. i , the predicted (log-transformed) PSA at time t is P SA
e ) (k) }, a 95% point-wise predictive interval for log-transformed PSA is then formed using 2.5% quantile to 97.5% quantile of {P SA i , k = 1, 2, · · · , m} for m draws. Examples of these predictive intervals on the original PSA scale are shown as shaded regions for the four patients in Figure 5 .
Note that the construction of predictive intervals at each time point is based on the assumption that HT is not given and that clinical recurrence events and death could be eliminated. This is not the same as the assumption that the patient is alive and is not given HT.
We note that patients (a) and (b), who have lots of data, have fairly narrow prediction intervals, whereas patient (c) and (d) have less follow-up and thus wider prediction intervals. We envision a graph like this would also be useful in monitoring the progression of the patient, for example if a new PSA value is measured and it falls outside the shaded region then this is indicative of the patient doing either worse than or better than expected. After a new measurement is obtained new graphs could be produced, thus giving real-time monitoring of a patient's progression. Table 2 shows the proportion of future PSA values amongst all available future data which were within the 95% prediction intervals, we see very good correspondence with the expected 95% level for all years. Table 3 compares the expected events and observed events. For a censored and alive subject i with survival information (t i , δ i = 0) with follow-up information (t * i , δ * i ), the expected number of events within (t i , t * i ] is P T i < t * i | X obs , Z . Now to calculate the expected number for 1 year, we get the follow-up time for all censored (δ i = 0) subjects, t * i − t i . If t * i − t i > 12, we set t 0 = 12, else we use t 0 = t * i − t i in P T i > t i + t 0 | T i > t i . By summing over i, we get the expected number of events in 0 ∼ 1 year. Similarly we can calculate expected number of events for 0 ∼ 2 years and 0 ∼ 3 years. From Table 3 , we can see that the observed number of recurrence events is much less than the expected number of events for all periods. One reason is that some patients get HT because of elevated PSA. But if we count HT as failure, then the numbers are much closer.
Another way to validate the survival model is to calculate the probability of recurrence within 3 years after the last contact time in the analysis data, P T i ≤ t i + 36 | X obs , Z, no HT in [t i , t i + 36] , for any censored and alive patient who had no HT before t i , and then compare with observed recurrence or HT. The calculated Kaplan-Meier estimate of the three year recurrence or hormonal therapy probability is shown in Figure 6 for five groups categorized by the estimated probability of recurrence within 3 years. The results show that a larger proportion of recurrences or HT patients in the groups with the higher predicted probability, this provides support for the validity of the model. For those who have small predicted probability (< 0.01), there were no recurrence
(1 received HT) within 3 years from the last contact time in the analysis data.
Sensitivity to Priors and Model Assumptions
Due to the large number of patients and longitudinal observations we have in the study, the posterior distributions of population parameters are dominated by data. So we expect our results to be quite robust to most prior specifications. Our limited experience with various prior specifications confirm that this is indeed the case for most parameters. We suspect that the variance term σ 44 for the distribution of R i4 in the cured group, together with the prior mean −6, might have some effects on the classification of the cure status of patients and hence affect the estimates of population parameters. We set a fairly informative prior for σ 44 to restrict the variation of R i4 for the random effects of cured group. Also the mean −6 is chosen rather empirically. These are just possible ways to separate into states (cured or not cured) for the patients. If we made the prior for σ 44 less restrictive and the prior mean of R i4 larger, we would have more patients with the probability of cure closer to 0.5 since the random effects model under both groups would fit the data equally well. On the other hand, if we set the prior mean of R i4 even smaller, we would have more unequivocal estimate of probability of cure, that is, many patients would have estimated probability of cure either closer to 1 or 0. Our experience with various values for both the prior for σ 44 and prior mean of R i4 found very little effect on the population parameters of the incidence model and failure time model. The prior mean but not the prior distribution of σ 44 affects individual prediction of cure status for some patients. For example, by setting -5 as the prior mean, we have 108 with predicted cure probability <= 0.05 , 36 with predicted cure probability >= 0.95, and 97 with predicted cure probability between 0.45 and 0.55 based on posterior draws of D; while by setting -7 as the prior mean, we have 137 with predicted cure probability <= 0.05, 39 with predicted cure probability >= 0.95, and 84 with predicted cure probability between 0.45 and 0.55. However about 90% of the patients have the difference of predicted cure probability less than 0.1 under the two different prior means. For the prediction distribution of cancer recurrence as described in Section 6, we find prediction curves within three years are nearly always very similar under the assumption of different prior means of R i4 .
The advantage of adding a cure model to the joint modeling setting is that it provides a way to model the heterogeneity due to the potential existence of long-term survivors and hence providing more accurate results. To assess the need for a cure model, we advocate using the conditional predictive ordinate (CPO). For a specific subject i under model M r , the CPO is defined by CPO (r) i = f r (x i,obs | X (i),obs ), the conditional density of the observed data for subject i,
x i,obs , given the observed data X (i),obs for all subjects except i. The CPO (r) i can be approximated from MCMC output by a harmonic mean formula (Gelfand 1995) ,
Computation of this approximation involves evaluation of f r (x i,obs | Ω r ) requires integration with respect to random effects R i and for a censored patient, it requires further integration with respect to latent variable D i . Simple simulation studies (without longitudinal data) in Yu (2004) found that CPO has better performance than the Bayesian information criterion (BIC) and the Bayes factors for assessing whether or not a model needed a cure component for survival data. By applying the CPO criteria to our prostate cancer study, we found that the difference in the summation of log-CPO, n i=1 log(CPO (r) i ) is 172 for joint models with cure models and without cure models. This supports the need for a cure component in the model.
Discussion
In prostate cancer, if the cancer cells are confined to the organ, there is high chance of killing these cancer cells by radiation and hence curing the patient of prostate cancer. These people will not experience recurrence of cancer and the probability of having recurrence is 0. However if cancer cells are not confined to the organ or not completely killed by radiation, then the patient is subject to recurrence. This is the biological reason for including a cure component in the model.
Yet we never observe cure for a patient if he is censored (had not experienced recurrence yet).
The logistic model provides estimation for the chance of being cured for such patients.
One issue that arises because of patients who received HT due to elevated PSA is dependent censoring. For such patients, had they not received HT, they would very likely experience cancer recurrence soon. The effect of HT postponed the time to recurrence. Adding HT as a time dependent covariate in a hazard model may not be quite correct from a causal inference viewpoint, but it maybe satisfactory for predictions. The decision to give HT is usually based on the value and slope of PSA, and these two variables are already in the model, thus adding HT to the model helps reduce the possible bias since for those patients, the observed time is delayed by HT.
The disadvantage of our model is that it is highly parameterized. With such complicated modeling, interpretation of the parameters can be hard, and furthermore there can be identifiability problems with cure models (Farewell 1986 and Li et al. 2001) . On the other hand, the slow progressive nature of prostate cancer also means that recurrences are possible many years after the initial treatment. Thus despite the strong scientific rationale for a cure component, it may be possible to fit these data without using a cure model. However, use of the CPO statistic suggests that models including a cured component give a better fit to the data. In this way the
